What the eyes see, the heart doesn’t grieve over
At IC Targets we are developing an innovative MRI technology for dramatically improved diagnosis and treatment monitoring of coronary heart disease and of other conditions leading to heart failure. The technology called MEMRI (manganese enhanced MRI) exploits the unique MRI and biological properties of the contrast agent mangafodipir. Competing imaging modalities such as x-ray and nuclear medicine provide mainly indirect measures of myocardial viability. MEMRI also has the additional advantages of providing a better image resolution and avoiding radiation.
Mangafodipir, now a generic product, was previously marketed by GE Healthcare for imaging of the liver and pancreas under the trade name Teslascan™. IC Targets has patented a new use of the contrast agent and aims to repositioning the contrast agent for viability assessment of the heart muscle. The product addresses an unmet medical need and has a reduced regulatory risk and time to market. The company has already generated promising proof-of-principle data in patients with heart failure and possesses a strong intellectual property rights portfolio.